Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· April 9, 2026

Bitcoin's Scariest Risk Just Became More Likely to Happen. Should You Sell It?

View original at nasdaq.com
Bitcoin's Scariest Risk Just Became More Likely to Happen. Should You Sell It? Key Points Bitcoin is secured by encryption. That encryption is thought to be very burdensome to break with normal computers…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Protocol upgrades will almost certainly arrive before any quantum machine can exploit the vulnerability for long-term investors

    60% confidence
  • A full migration to quantum-resistant cryptography for Bitcoin could take about seven years

    60% confidence
  • The encryption-breaking risk posed by quantum computers wouldn't pose an actual threat for approximately 10 years (prior to Google's new research)

    60% confidence
  • If you need the money within five years, this new paper is a reason to temper your Bitcoin allocation

    60% confidence
  • Stock Advisor's total average return is 946% compared to 190% for the S&P 500

    60% confidence
  • Bitcoin was not identified as one of the 10 best stocks for investors to buy now

    60% confidence
  • The quantum threat window just shrank from a comfortable decade to perhaps five to seven years

    60% confidence
  • Bitcoin's encryption can be cracked within minutes by an optimized quantum computer that needs 20X fewer physical qubits than prior estimates

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
Bitcoin's Scariest Risk Just Became More Likely to Happen. Should You Sell It? — Source | Via News | Via News